Cell cycle arrest in a model of colistin nephrotoxicity

Physiological Genomics

Volumn 45, Issue 19, 2013, Pages 877-888

  Eadon, Michael T ^a   Hack, Bradley K ^b   Alexander, Jessy J ^c   Xu, Chang ^b   Dolan, M Eileen ^b   Cunningham, Patrick N ^b  

^a INDIANA UNIVERSITY   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

Author keywords

Cell cycle; Colistin; Galectin 3; Nephrotoxicity; Polymyxin E; Renal failure

Indexed keywords

COLISTIN; CREATININE; CYCLIN B1; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; RNA;

ACUTE KIDNEY TUBULE NECROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; KIDNEY INJURY; MALE; MOUSE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UREA NITROGEN BLOOD LEVEL;

CELL CYCLE; COLISTIN; GALECTIN-3; NEPHROTOXICITY; POLYMYXIN E; RENAL FAILURE;

ANIMALS; BODY WEIGHT; CELL CYCLE CHECKPOINTS; CLUSTER ANALYSIS; COLISTIN; DISEASE MODELS, ANIMAL; GALECTIN 3; GENE EXPRESSION PROFILING; IN SITU NICK-END LABELING; KIDNEY; KIDNEY TUBULES; MALE; MICE; MICE, INBRED C57BL; NECROSIS; PROLIFERATING CELL NUCLEAR ANTIGEN; REPRODUCIBILITY OF RESULTS;

EID: 84884959793     PISSN: 10948341     EISSN: 15312267     Source Type: Journal    
DOI: 10.1152/physiolgenomics.00076.2013     Document Type: Article

References (69)

1. Amin RP, Vickers AE, Sistare F, Thompson KL, Roman RJ, Lawton M, Kramer J, Hamadeh HK, Collins J, Grissom S, Bennett L, Tucker CJ, Wild S, Kind C, Oreffo V, Davis JW 2nd, Curtiss S, Naciff JM, Cunningham M, Tennant R, Stevens J, Car B, Bertram TA, Afshari CA. Identification of putative gene based markers of renal toxicity. Environ Health Perspect 112: 465-479, 2004.
2. Banfi G, Mazzucco G, Barbiano di Belgiojoso G, Bestetti Bosisio M, Stratta P, Confalonieri R, Ferrario F, Imbasciati E, Monga G. Morphological parameters in lupus nephritis: their relevance for classification and relationship with clinical and histological findings and outcome. Q J Med 55: 153-168, 1985.
3. Bonventre JV. Kidney injury molecule-1 (KIM-1): a specific and sensitive biomarker of kidney injury. Scand J Clin Lab Invest Suppl 241: 78-83, 2008.
4. Brown MR, Melling J. Role of divalent cations in the action of polymyxin B and EDTA on Pseudomonas aeruginosa. J Gen Microbiol 59: 263-274, 1969.
5. Chen JJ, Hsueh HM, Delongchamp RR, Lin CJ, Tsai CA. Reproducibility of microarray data: a further analysis of microarray quality control (MAQC) data. BMC Bioinformatics 8: 412, 2007.
6. Chertow GM, Burdick E, Honour M, Bonventre JV, Bates DW. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol 16: 3365-3370, 2005.
7. Connolly KM, Bogdanffy MS. Evaluation of proliferating cell nuclear antigen (PCNA) as an endogenous marker of cell proliferation in rat liver: a dual-stain comparison with 5-bromo-2=-deoxyuridine. J Histochem Cytochem 41: 1-6, 1993.
8. Couet W, Gregoire N, Gobin P, Saulnier PJ, Frasca D, Marchand S, Mimoz O. Pharmacokinetics of colistin and colistimethate sodium after a single 80-mg intravenous dose of CMS in young healthy volunteers. Clin Pharmacol Ther 89: 875-879, 2011.
9. Cui Y, Paules RS. Use of transcriptomics in understanding mechanisms of drug-induced toxicity. Pharmacogenomics 11: 573-585, 2010.
10. Cunningham PN, Hack BK, Ren G, Minto AW, Morgan BP, Quigg RJ. Glomerular complement regulation is overwhelmed in passive Heymann nephritis. Kidney Int 60: 900-909, 2001.
11. Dai C, Zhang D, Li J. Effect of colistin exposure on calcium homeostasis and mitochondria functions in chick cortex neurons. Toxicol Mech Meth 23: 281-288, 2013.
12. Dang Z, MacKinnon A, Marson LP, Sethi T. Tubular atrophy and interstitial fibrosis after renal transplantation is dependent on galectin-3. Transplantation 93: 477-484, 2012.
13. Davis SD. Activity of gentamicin, tobramycin, polymyxin B, and colistimethate in mouse protection tests with Pseudomonas aeruginosa. Antimicrob Agents Chemother 8: 50-53, 1975.
14. Deryke CA, Crawford AJ, Uddin N, Wallace MR. Colistin dosing and nephrotoxicity in a large community teaching hospital. Antimicrob Agents Chemother 54: 4503-4505, 2010.
15. Eadon MT, Hack BK, Xu C, Ko B, Toback FG, Cunningham PN. Endotoxemia alters tight junction gene and protein expression in the kidney. Am J Physiol Renal Physiol 303: F821-F830, 2012.
16. Evans ME, Feola DJ, Rapp RP. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother 33: 960-967, 1999.
17. Falagas ME, Kasiakou SK. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care 10: R27, 2006.
18. Fridman JS, Lowe SW. Control of apoptosis by p53. Oncogene 22: 9030-9040, 2003.
19. Glotzer M, Murray AW, Kirschner MW. Cyclin is degraded by the ubiquitin pathway. Nature 349: 132-138, 1991.
20. Gudowski G, Schneeweiss B, Briedigkeit W, Staudt J, Robbe K, Dieckhoff J, Adrian B, Michel A, Hodi J, Tschauschev P. [Results of animal experiments on toxic organ damages under longterm antibiotic therapy (binotal, colimycine)]. Dtsch Gesundheitsw 25: 2349-2355, 1970.
21. Hakim A, Kallel H, Sahnoun Z, Badraoui R, Jammoussi K, Bouaziz M, Zeghal KM, Rebaii T. Lack of nephrotoxicity following 15-day therapy with high doses of colistin in rats. Med Sci Monit 14: BR74-BR77, 2008.
22. Hartzell JD, Neff R, Ake J, Howard R, Olson S, Paolino K, Vishnepolsky M, Weintrob A, Wortmann G. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis 48: 1724-1728, 2009.
23. Hermeking H, Lengauer C, Polyak K, He TC, Zhang L, Thiagalingam S, Kinzler KW, Vogelstein B. 14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell 1: 3-11, 1997.
24. Ho JE, Liu C, Lyass A, Courchesne P, Pencina MJ, Vasan RS, Larson MG, Levy D. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J Am Coll Cardiol 60: 1249-1256, 2012.
25. Hodeify R, Megyesi J, Tarcsafalvi A, Safirstein RL, Price PM. Protection of cisplatin cytotoxicity by an inactive cyclin-dependent kinase. Am J Physiol Renal Physiol 299: F112-F120, 2010.
26. Hodeify R, Tarcsafalvi A, Megyesi J, Safirstein RL, Price PM. Cdk2-dependent phosphorylation of p21 regulates the role of Cdk2 in cisplatin cytotoxicity. Am J Physiol Renal Physiol 300: F1171-F1179, 2011.
27. Huang da W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucl Acids Res 37: 1-13, 2009.
28. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44-57, 2009.
29. Iacobini C, Menini S, Oddi G, Ricci C, Amadio L, Pricci F, Olivieri A, Sorcini M, Di Mario U, Pesce C, Pugliese G. Galectin-3/AGE-receptor 3 knockout mice show accelerated AGE-induced glomerular injury: evidence for a protective role of galectin-3 as an AGE receptor. FASEB J 18: 1773-1775, 2004.
30. Iacobini C, Oddi G, Menini S, Amadio L, Ricci C, Di Pippo C, Sorcini M, Pricci F, Pugliese F, Pugliese G. Development of age-dependent glomerular lesions in galectin-3/AGE-receptor-3 knockout mice. Am J Physiol Renal Physiol 289: F611-F621, 2005.
31. Jeffery IB, Higgins DG, Culhane AC. Comparison and evaluation of methods for generating differentially expressed gene lists from microarray data. BMC Bioinformatics 7: 359, 2006.
32. Kashani K, Al-Khafaji A, Ardiles T, Artigas A, Bagshaw SM, Bell M, Bihorac A, Birkhahn R, Cely CM, Chawla LS, Davison DL, Feldkamp T, Forni LG, Gong MN, Gunnerson KJ, Haase M, Hackett J, Honore PM, Hoste EA, Joannes-Boyau O, Joannidis M, Kim P, Koyner JL, Laskowitz DT, Lissauer ME, Marx G, McCullough PA, Mullaney S, Ostermann M, Rimmele T, Shapiro NI, Shaw AD, Shi J, Sprague AM, Vincent JL, Vinsonneau C, Wagner L, Walker MG, Wilkerson RG, Zacharowski K, Kellum JA. Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. Crit Care 17: R25, 2013.
33. Kim HR, Lin HM, Biliran H, Raz A. Cell cycle arrest and inhibition of anoikis by galectin-3 in human breast epithelial cells. Cancer Res 59: 4148-4154, 1999.
34. Kim J, Lee KH, Yoo S, Pai H. Clinical characteristics and risk factors of colistin-induced nephrotoxicity. Int J Antimicrob Agents 34: 434-438, 2009.
35. Ko H, Jeon M, Choo E, Lee E, Kim T, Jun JB, Gil HW. Early acute kidney injury is a risk factor that predicts mortality in patients treated with colistin. Nephron Clin Pract 117: c284-c288, 2011.
36. Kuwabara T, Mori K, Mukoyama M, Kasahara M, Yokoi H, Saito Y, Yoshioka T, Ogawa Y, Imamaki H, Kusakabe T, Ebihara K, Omata M, Satoh N, Sugawara A, Barasch J, Nakao K. Urinary neutrophil gelatinase-associated lipocalin levels reflect damage to glomeruli, proximal tubules, and distal nephrons. Kidney Int 75: 285-294, 2009.
37. Kwon JA, Lee JE, Huh W, Peck KR, Kim YG, Kim DJ, Oh HY. Predictors of acute kidney injury associated with intravenous colistin treatment. Int J Antimicrob Agents 35: 473-477, 2010.
38. Li J, Milne RW, Nation RL, Turnidge JD, Smeaton TC, Coulthard K. Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate. J Antimicrob Chemother 53: 837-840, 2004.
39. Li J, Milne RW, Nation RL, Turnidge JD, Smeaton TC, Coulthard K. Use of high-performance liquid chromatography to study the pharmacokinetics of colistin sulfate in rats following intravenous administration. Antimicrob Agents Chemother 47: 1766-1770, 2003.
40. Li J, Nation RL, Milne RW, Turnidge JD, Coulthard K. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int J Antimicrob Agents 25: 11-25, 2005.
41. Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, Paterson DL. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 6: 589-601, 2006.
42. Lin B, Zhang C, Xiao X. Toxicity, bioavailability and pharmacokinetics of a newly formulated colistin sulfate solution. J Vet Pharmacol Ther 28: 349-354, 2005.
43. Lin HM, Moon BK, Yu F, Kim HR. Galectin-3 mediates genisteininduced G(2)/M arrest and inhibits apoptosis. Carcinogenesis 21: 1941-1945, 2000.
44. Ma Z, Wang J, Nation RL, Li J, Turnidge JD, Coulthard K, Milne RW. Renal disposition of colistin in the isolated perfused rat kidney. Antimicrob Agents Chemother 53: 2857-2864, 2009.
45. Marchand S, Lamarche I, Gobin P, Couet W. Dose-ranging pharmacokinetics of colistin methanesulphonate (CMS) and colistin in rats following single intravenous CMS doses. J Antimicrob Chemother 65: 1753-1758, 2010.
46. Megyesi J, Andrade L, Vieira JM Jr, Safirstein RL, Price PM. Coordination of the cell cycle is an important determinant of the syndrome of acute renal failure. Am J Physiol Renal Physiol 283: F810-F816, 2002.
47. Megyesi J, Safirstein RL, Price PM. Induction of p21WAF1/CIP1/SDI1 in kidney tubule cells affects the course of cisplatin-induced acute renal failure. J Clin Invest 101: 777-782, 1998.
48. Mehta RL, Pascual MT, Soroko S, Savage BR, Himmelfarb J, Ikizler TA, Paganini EP, Chertow GM. Spectrum of acute renal failure in the intensive care unit: the PICARD experience. Kidney Int 66: 1613-1621, 2004.
49. Nepal M, Bock GH, Sehic AM, Schultz MF, Zhang PL. Kidney injury molecule-1 expression identifies proximal tubular injury in urate nephropathy. Ann Clin Lab Sci 38: 210-214, 2008.
50. Nishiyama J, Kobayashi S, Ishida A, Nakabayashi I, Tajima O, Miura S, Katayama M, Nogami H. Up-regulation of galectin-3 in acute renal failure of the rat. Am J Pathol 157: 815-823, 2000.
51. Nomura A, Nishikawa K, Yuzawa Y, Okada H, Okada N, Morgan BP, Piddlesden SJ, Nadai M, Hasegawa T, Matsuo S. Tubulointerstitial injury induced in rats by a monoclonal antibody that inhibits function of a membrane inhibitor of complement. J Clin Invest 96: 2348-2356, 1995.
52. Okamura DM, Pasichnyk K, Lopez-Guisa JM, Collins S, Hsu DK, Liu FT, Eddy AA. Galectin-3 preserves renal tubules and modulates extracellular matrix remodeling in progressive fibrosis. Am J Physiol Renal Physiol 300: F245-F253, 2011.
53. Paul M, Bishara J, Levcovich A, Chowers M, Goldberg E, Singer P, Lev S, Leon P, Raskin M, Yahav D, Leibovici L. Effectiveness and safety of colistin: prospective comparative cohort study. J Antimicrob Chemother 65: 1019-1027, 2010.
54. Price PM, Megyesi J, Safirstein RL. Cell cycle regulation: repair and regeneration in acute renal failure. Semin Nephrol 23: 449-459, 2003.
55. Price PM, Safirstein RL, Megyesi J. The cell cycle and acute kidney injury. Kidney Int 76: 604-613, 2009.
56. Pugliese G, Pricci F, Iacobini C, Leto G, Amadio L, Barsotti P, Frigeri L, Hsu DK, Vlassara H, Liu FT, Di Mario U. Accelerated diabetic glomerulopathy in galectin-3/AGE receptor 3 knockout mice. FASEB J 15: 2471-2479, 2001.
57. Rouse RL, Zhang J, Stewart SR, Rosenzweig BA, Espandiari P, Sadrieh NK. Comparative profile of commercially available urinary biomarkers in preclinical drug-induced kidney injury and recovery in rats. Kidney Int 79: 1186-1197, 2011.
58. Santamaria C, Mykietiuk A, Temporiti E, Stryjewski ME, Herrera F, Bonvehi P. Nephrotoxicity associated with the use of intravenous colistin. Scand J Infect Dis 41: 767-769, 2009.
59. Sarkar S, DeSantis ER, Kuper J. Resurgence of colistin use. Am J Health Syst Pharm 64: 2462-2466, 2007.
60. Speidel D. Transcription-independent p53 apoptosis: an alternative route to death. Trends Cell Biol 20: 14-24, 2010.
61. van der Velde AR, Gullestad L, Ueland T, Aukrust P, Guo Y, Adourian A, Muntendam P, van Veldhuisen DJ, de Boer RA. Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH. Circ Heart Fail 6: 219-226, 2013.
62. Wallace SJ, Li J, Nation RL, Rayner CR, Taylor D, Middleton D, Milne RW, Coulthard K, Turnidge JD. Subacute toxicity of colistin methanesulfonate in rats: comparison of various intravenous dosage regimens. Antimicrob Agents Chemother 52: 1159-1161, 2008.
63. Wang D, Kong L, Wang J, He X, Li X, Xiao Y. Polymyxin E sulfate-loaded liposome for intravenous use: preparation, lyophilization, and toxicity assessment in vivo. PDA J Pharm Sci Technol 63: 159-167, 2009.
64. Wu X, Guo R, Chen P, Wang Q, Cunningham PN. TNF induces caspase-dependent inflammation in renal endothelial cells through a Rhoand myosin light chain kinase-dependent mechanism. Am J Physiol Renal Physiol 297: F316-F326, 2009.
65. Yang J, Bardes ES, Moore JD, Brennan J, Powers MA, Kornbluth S. Control of cyclin B1 localization through regulated binding of the nuclear export factor CRM1. Genes Dev 12: 2131-2143, 1998.
66. Yang L, Besschetnova TY, Brooks CR, Shah JV, Bonventre JV. Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury. Nat Med 16: 535-543, 2010.
67. Yousef JM, Chen G, Hill PA, Nation RL, Li J. Ascorbic acid protects against the nephrotoxicity and apoptosis caused by colistin and affects its pharmacokinetics. J Antimicrob Chemother 67: 452-459, 2012.
68. Yousef JM, Chen G, Hill PA, Nation RL, Li J. Melatonin attenuates colistin-induced nephrotoxicity in rats. Antimicrob Agents Chemother 55: 4044-4049, 2011.
69. Yu F, Megyesi J, Safirstein RL, Price PM. Identification of the functional domain of p21(WAF1/CIP1) that protects cells from cisplatin cytotoxicity. Am J Physiol Renal Physiol 289: F514-F520, 2005.